HilleVax, Inc., (HLVX) News
Filter HLVX News Items
HLVX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HLVX News Highlights
- For HLVX, its 30 day story count is now at 2.
- Over the past 13 days, the trend for HLVX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest HLVX News From Around the Web
Below are the latest news stories about HILLEVAX INC that investors may wish to consider to help them evaluate HLVX as an investment opportunity.
Insider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 10,000 Shares of HilleVax Inc ...In a notable insider transaction, Chief Medical Officer Astrid Borkowski sold 10,000 shares of HilleVax Inc (NASDAQ:HLVX) on December 15, 2023. |
Insider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 20,000 Shares of HilleVax Inc ...In a notable insider transaction, Chief Medical Officer Astrid Borkowski sold 20,000 shares of HilleVax Inc (NASDAQ:HLVX) on December 4, 2023. |
Wall Street Analysts Believe HilleVax, Inc. (HLVX) Could Rally 92.19%: Here's is How to TradeThe mean of analysts' price targets for HilleVax, Inc. (HLVX) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
HilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the UpgradeHilleVax, Inc. (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Does HilleVax, Inc. (HLVX) Have the Potential to Rally 107.23% as Wall Street Analysts Expect?The mean of analysts' price targets for HilleVax, Inc. (HLVX) points to a 107.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressBOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended September 30, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. “HilleVax is advancin |
HilleVax to Present at Upcoming Investor ConferencesBOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York, New York on Monday, November 6, 2023 at 3:10 p.m. EST and at the Stifel Healthcare Conference in New York, New York, on Tuesday, November 14, 2023 at 11:30 a.m. EST. HIL-214, HilleVax’s invest |
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare ConferenceBOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 2023 Cantor Global Healthcare Conference in New York, New York on Thursday, September 28, 2023 at 12:40 p.m. EST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the r |
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional SharesBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it has closed its previously announced underwritten public offering of 9,200,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,200,000 additional shares, at a price to the public of $12.50 per share. All of the shares in the offering we |
Owning 32% shares,institutional owners seem interested in HilleVax, Inc. (NASDAQ:HLVX),Key Insights Institutions' substantial holdings in HilleVax implies that they have significant influence over the... |